Last reviewed · How we verify
Meningococcal carrier state
Approved treatments
- RIFAMPIN
Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Meningococcal carrier state patent landscape — cliff calendar, originator estates, attackable patents
- Meningococcal carrier state treatment landscape brief
- Meningococcal carrier state treatment updates RSS
Frequently asked questions about Meningococcal carrier state
What drugs treat Meningococcal carrier state?
Tracked treatments include RIFAMPIN.
What is the treatment for Meningococcal carrier state?
Standard treatment for Meningococcal carrier state includes RIFAMPIN. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Meningococcal carrier state patent cliff · Meningococcal carrier state CI report
- Treatment: RIFAMPIN
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing